David O. Watson Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

David O. Watson is General Counsel of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 117,721 shares of APLS, which is worth approximately $3.23 Million. The most recent transaction as insider was on Sep 27, 2024, when has been sold 10,569 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 118K

9.86% 3M change

37.28% 12M change

Total Value Held $3.23 Million

David O. Watson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 27 2024	BUY Bona fide gift	-	10,569 Added 8.24%	117,721 Common Stock
Mar 06 2024	BUY Exercise of conversion of derivative security	$52,103 $13.85 p/Share	3,762 Added 3.39%	107,152 Common Stock
Feb 12 2024	SELL Open market or private sale	$52,928 $67.77 p/Share	781 Reduced 0.75%	103,390 Common Stock
Jan 29 2024	SELL Open market or private sale	$58,110 $64.14 p/Share	906 Reduced 0.86%	104,171 Common Stock
Jan 22 2024	SELL Open market or private sale	$271,960 $65.0 p/Share	4,184 Reduced 3.83%	105,077 Common Stock
Jan 16 2024	SELL Open market or private sale	$283,274 $66.81 p/Share	4,240 Reduced 3.74%	109,261 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	23,748 Added 17.3%	113,501 Common Stock
Dec 19 2023	SELL Open market or private sale	$223,326 $57.19 p/Share	3,905 Reduced 4.17%	89,753 Common Stock
Dec 19 2023	BUY Exercise of conversion of derivative security	$109,484 $13.85 p/Share	7,905 Added 7.78%	93,658 Common Stock
Jul 03 2023	SELL Open market or private sale	$765,729 $89.98 p/Share	8,510 Reduced 9.03%	85,753 Common Stock
Jun 28 2023	SELL Bona fide gift	-	12,750 Reduced 11.91%	94,263 Common Stock
Apr 21 2023	SELL Bona fide gift	-	67,955 Reduced 38.84%	107,013 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$48,262 $58.5 p/Share	825 Reduced 0.47%	174,968 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	9,886 Added 5.32%	175,793 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$27,243 $51.21 p/Share	532 Reduced 0.32%	165,907 Common Stock
Jan 27 2023	SELL Payment of exercise price or tax liability	$29,076 $52.77 p/Share	551 Reduced 0.33%	166,439 Common Stock
Jan 20 2023	SELL Payment of exercise price or tax liability	$105,869 $52.05 p/Share	2,034 Reduced 1.2%	166,990 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	53,455 Added 24.03%	169,024 Common Stock
Jun 22 2022	SELL Open market or private sale	$445,100 $44.51 p/Share	10,000 Reduced 7.96%	115,569 Common Stock
Apr 25 2022	SELL Open market or private sale	$250,000 $50.0 p/Share	5,000 Reduced 3.83%	125,569 Common Stock
Apr 21 2022	SELL Other acquisition or disposition	-	1,875 Reduced 1.42%	130,569 Common Stock
Feb 10 2022	SELL Payment of exercise price or tax liability	$23,136 $47.12 p/Share	491 Reduced 0.37%	132,444 Common Stock
Jan 28 2022	SELL Payment of exercise price or tax liability	$25,084 $38.59 p/Share	650 Reduced 0.49%	132,935 Common Stock
Jan 21 2022	BUY Grant, award, or other acquisition	-	26,051 Added 16.32%	133,585 Common Stock
Dec 27 2021	SELL Open market or private sale	$58,200 $48.5 p/Share	1,200 Reduced 1.1%	107,534 Common Stock

DOW

David O. Watson

General Counsel

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account